William Blair Analysts Boost Earnings Estimates for Xencor

Key Points

• William Blair analysts have upgraded their Q3 2025 earnings per share (EPS) estimate for Xencor, expecting it to be ($0.83), an improvement from their previous estimate of ($0.89), and they maintain an "Outperform" rating on the stock.
• In its latest earnings report, Xencor posted ($0.41) EPS, significantly beating the consensus estimate of ($0.78), with a revenue of $43.61 million, reflecting an 82.4% increase year-over-year.
• Xencor's stock is facing mixed ratings from analysts, with reports of lowered price targets from major firms, resulting in an overall average rating of "Moderate Buy" based on a target price of $26.43.

Xencor, Inc. (NASDAQ:XNCR - Free Report) - Analysts at William Blair boosted their Q3 2025 earnings per share (EPS) estimates for Xencor in a note issued to investors on Wednesday, August 6th. William Blair analyst M. Phipps now expects that the biopharmaceutical company will post earnings per share of ($0.83) for the quarter, up from their prior forecast of ($0.89). William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Xencor's current full-year earnings is ($3.68) per share. William Blair also issued estimates for Xencor's Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($2.83) EPS, Q1 2026 earnings at ($0.90) EPS, Q2 2026 earnings at ($0.85) EPS, Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.81) EPS, FY2026 earnings at ($3.39) EPS, FY2027 earnings at ($3.24) EPS and FY2028 earnings at ($3.34) EPS.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) EPS for the quarter, beating analysts' consensus estimates of ($0.78) by $0.37. Xencor had a negative net margin of 121.52% and a negative return on equity of 25.75%. The firm had revenue of $43.61 million during the quarter, compared to the consensus estimate of $22.59 million. During the same quarter last year, the firm earned ($1.07) EPS. The firm's revenue for the quarter was up 82.4% compared to the same quarter last year.

XNCR has been the subject of a number of other research reports. Barclays lowered their price target on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a report on Thursday, May 8th. Wedbush lowered their price target on shares of Xencor from $31.00 to $26.00 and set an "outperform" rating for the company in a report on Thursday. Finally, Wells Fargo & Company lowered their price target on shares of Xencor from $33.00 to $27.00 and set an "overweight" rating for the company in a report on Thursday. Two equities research analysts have rated the stock with a sell rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $26.43.

Xencor Trading Down 1.2%

Shares of NASDAQ:XNCR opened at $7.23 on Monday. Xencor has a 12 month low of $7.07 and a 12 month high of $27.24. The company has a 50-day moving average price of $8.67 and a 200 day moving average price of $10.87. The company has a market cap of $515.64 million, a price-to-earnings ratio of -3.01 and a beta of 0.89.

Insider Buying and Selling at Xencor

In other Xencor news, Director Kurt A. Gustafson sold 2,993 shares of the company's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $9.22, for a total value of $27,595.46. Following the transaction, the director owned 20,183 shares of the company's stock, valued at $186,087.26. This represents a 12.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Ellen Feigal sold 2,993 shares of the company's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $9.22, for a total value of $27,595.46. Following the completion of the transaction, the director directly owned 19,183 shares in the company, valued at $176,867.26. This trade represents a 13.50% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,194 shares of company stock valued at $103,209 in the last quarter. 5.23% of the stock is owned by insiders.

Institutional Trading of Xencor

Institutional investors and hedge funds have recently modified their holdings of the stock. Sterling Capital Management LLC raised its stake in shares of Xencor by 732.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 1,040 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Xencor during the fourth quarter valued at approximately $34,000. State of Wyoming bought a new stake in shares of Xencor during the first quarter valued at approximately $34,000. CWM LLC raised its stake in shares of Xencor by 195.5% during the first quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company's stock valued at $36,000 after acquiring an additional 2,231 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its stake in shares of Xencor by 82.8% during the second quarter. PNC Financial Services Group Inc. now owns 5,982 shares of the biopharmaceutical company's stock valued at $47,000 after acquiring an additional 2,709 shares in the last quarter.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.